BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/12/20
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/12/20
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar DisordersGlobeNewsWire • 11/11/20
BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer's 35th Anniversary Annual MeetingGlobeNewsWire • 11/09/20
BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and WebcastGlobeNewsWire • 11/05/20
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with DeliriumGlobeNewsWire • 10/26/20
BioXcel Therapeutics: Opportunity Emerges During Pandemic While Mental Health Is Being IgnoredSeeking Alpha • 09/23/20
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20
BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/14/20
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/20
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and WebcastGlobeNewsWire • 08/07/20
Bioxcel Therapeutics Hits Record On Bullish Test Results In SchizophreniaInvestors Business Daily • 07/20/20
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar DisorderGlobeNewsWire • 07/20/20
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and AgitationGlobeNewsWire • 07/09/20
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating AgitationGlobeNewsWire • 07/07/20
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development OfficerGlobeNewsWire • 06/23/20
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial OfficerGlobeNewsWire • 06/16/20